Alerts
Modified Hours for Martin Luther King Jr. Day

In recognition of the upcoming Martin Luther King Jr. Day holiday, some of The University of Kansas Cancer Center’s offices will have modified hours on Monday, January 19, 2026.

More info
Staying Healthy During Influenza Season

The University of Kansas Health System is experiencing a high volume of patients seeking care for influenza and other respiratory illnesses. Whether you plan to visit the health system or not, learn how to keep yourself healthy.

More info
Skip Navigation

A PHASE 1 STUDY OF REVUMENIB, AZACITIDINE, AND VENETOCLAX AND IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT06177067

Study #:
CMH - RAVAML

Start Date:
Feb 05, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06177067

View Complete Trial Details & Eligibility at ClinicalTrials.gov

To request an appointment, call 844-323-1227.